Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women
Three years of daily K2 (MK-7) supported bone strength — evidence for the vitamin that helps guide calcium to where it belongs.
An independent summary of published ingredient research, not the original paper or a clinical study of CORE49.
What the research found
Researchers followed healthy postmenopausal women for three years to assess a low-dose MK-7 intervention. The paper reports changes in measures of bone health and age-related bone loss.
The important context
The findings concern a specific population and long-term protocol. They do not establish fracture prevention or the same outcome in younger adults, men or users of a blended supplement.
Where CORE49 fits
This paper informs our understanding of an individual ingredient. It did not evaluate the finished CORE49 formula. Study populations, ingredient forms and amounts can differ from those in our daily drink; ingredient evidence and formula evidence are not interchangeable.
